SSG
BIO icon

Summit Securities Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Summit Securities Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-28
Closed -$11K – 587
2023
Q2 		$11K Sell
28
-15
-35% -$6.1K ﹤0.01% 758
2023
Q1 		$21K Buy
43
+21
+95% +$9.83K ﹤0.01% 619
2022
Q4 		$9K Buy
+22
New +$8.88K ﹤0.01% 1041
2022
Q3 		– Sell
-45
Closed -$22K – 938
2022
Q2 		$22K Buy
45
+36
+400% +$18.7K ﹤0.01% 746
2022
Q1 		$5K Buy
+9
New +$5.42K ﹤0.01% 960

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Summit Securities Group's BIO Position: Q3 2023 in Review

Summit Securities Group sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2023, closing a stake of 28 shares — an estimated $11K sold.

Summit Securities Group first reported a position in BIO in Q1 2022 and held it in 5 quarters. The position peaked at $22K in Q2 2022. 468 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

  • Summit Securities Group reported no remaining Bio-Rad Laboratories Class A position as of Q3 2023 after selling out during the quarter.
  • Summit Securities Group sold 28 Bio-Rad Laboratories Class A shares in Q3 2023, an estimated $11K.
  • Summit Securities Group first reported a position in Bio-Rad Laboratories Class A in Q1 2022 and held it in 5 quarters.
  • Summit Securities Group's Bio-Rad Laboratories Class A position peaked at $22K in Q2 2022.
  • 468 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on Summit Securities Group's 13F filing for Q3 2023, filed 13 Nov 2023.